Project #81: Exploring the Therapeutic Potential of a Novel IRE1 Inhibitor in Type 1 Diabetes
Forecasted
This grant supports research on a novel IRE1 inhibitor to protect beta cells by reducing ER stress in Type 1 Diabetes, funded by Diabetes Research Connection.
Funder: Diabetes Research Connection
Due Dates (Anticipated): July 2027 (RFA opening, projected) | July 2027 (RFA deadline, projected)
Funding Amounts: Up to $75,000 per project for one year; graduate students eligible for up to $50,000, postdocs/assistant professors up to $75,000.
Summary: Supports early-career researchers investigating innovative approaches to protect insulin-producing beta cells in Type 1 Diabetes, with a focus on ER stress and beta cell survival.
Key Information: Only early-career researchers at U.S. institutions are eligible; research must focus on Type 1 Diabetes.
Description
This grant supports early-career scientists conducting innovative, early-stage research projects aimed at understanding, preventing, or treating Type 1 Diabetes (T1D). The specific focus of this cycle is on strategies to protect insulin-producing beta cells, particularly through approaches that address endoplasmic reticulum (ER) stress—a key contributor to beta cell dysfunction and destruction in T1D. The funder, Diabetes Research Connection (DRC), provides seed funding to help researchers generate proof-of-concept data, which can be leveraged for larger grants in the future. Projects must be completed within one year and are selected through a rigorous, peer-reviewed process.
